




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁴ : C12N 15/00, C07K 15/00 A61K 39/395, C07K 3/18 C12N 5/00, C12P 21/00 G01N 33/563</p>	<p>A1</p>	<p>(11) International Publication Number: WO 86/ 01533</p> <p>(43) International Publication Date: 13 March 1986 (13.03.86)</p>
<p>(21) International Application Number: PCT/GB85/00392</p> <p>(22) International Filing Date: 3 September 1985 (03.09.85)</p> <p>(31) Priority Application Number: 8422238</p> <p>(32) Priority Date: 3 September 1984 (03.09.84)</p> <p>(33) Priority Country: GB</p> <p>(71) Applicant (for all designated States except US): CELL-TECH LIMITED [GB/GB]; 244-250 Bath Road, Slough, Berkshire SL1 4DY (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only) : NEUBERGER, Michael, Samuel [GB/GB]; 34 Bateman Street, Cambridge CB2 1MA (GB). RABBITS, Terence, Howard [GB/GB]; Woodside, High Street, Hildersham, Cambridge CB1 6BU (GB).</p>	<p>(74) Agent: VOTIER, Sidney, David; Carpmals and Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).</p> <p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB, GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.</p> <p>Published <i>With international search report.</i></p>	

(54) Title: PRODUCTION OF CHIMERIC ANTIBODIES



(57) Abstract


A process for the production of a chimeric antibody, comprising: a) preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence comprising a first part which encodes at least the variable region of the heavy or light chain of an Ig molecule and a second part which encodes at least part of a second protein; b) if necessary, preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least the variable region of a complementary light or heavy chain respectively of an Ig molecule; c) transforming an immortalised mammalian cell line with the or both prepared vectors; and d) culturing said transformed cell line to produce the chimeric antibody; chimeric antibodies produced by this process; and plasmids and transformed cell lines used in the process.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 4 : C12N 15/00, C07K 15/00 A61K 39/395, C07K 3/18 C12N 5/00, C12P 21/00 G01N 33/563</p>	A1	<p>(11) International Publication Number: WO 86/ 01533</p> <p>(43) International Publication Date: 13 March 1986 (13.03.86)</p>
<p>(21) International Application Number: PCT/GB85/00392</p> <p>(22) International Filing Date: 3 September 1985 (03.09.85)</p> <p>(31) Priority Application Number: 8422238</p> <p>(32) Priority Date: 3 September 1984 (03.09.84)</p> <p>(33) Priority Country: GB</p> <p>(71) Applicant (for all designated States except US): CELL-TECH LIMITED [GB/GB]; 244-250 Bath Road, Slough, Berkshire SL1 4DY (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): NEUBERGER, Michael, Samuel [GB/GB]; 34 Bateman Street, Cambridge CB2 1MA (GB). RABBITS, Terence, Howard [GB/GB]; Woodside, High Street, Hildersham, Cambridge CB1 6BU (GB).</p>	<p>(74) Agent: VOTIER, Sidney, David; Carpmaels and Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).</p> <p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB, GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.</p> <p>Published With international search report.</p>	

(54) Title: PRODUCTION OF CHIMERIC ANTIBODIES



(57) Abstract

A process for the production of a chimeric antibody, comprising: a) preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence comprising a first part which encodes at least the variable region of the heavy or light chain of an Ig molecule and a second part which encodes at least part of a second protein; b) if necessary, preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least the variable region of a complementary light or heavy chain respectively of an Ig molecule; c) transfecting an immortalised mammalian cell line with the or both prepared vectors; and d) culturing said transformed cell lines to produce the chimeric antibody; chimeric antibodies produced by this process; and plasmids and transformed cell lines used in the process.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

- 1 -

PRODUCTION OF CHIMERIC ANTIBODIES

The present invention relates to a process for the production of chimeric antibodies using recombinant DNA techniques.

In the present application, the term 'chimeric antibody' is used to describe a protein comprising at least the antigen binding portion of an immunoglobulin molecule (Ig) attached by peptide linkage to at least part of another protein.

In recent years, advances in molecular biology based on recombinant DNA techniques have provided processes for the production of a wide range of heterologous polypeptides by transformation of host cells with heterologous DNA sequences which code for the production of the desired products.

EP-A-O 088 994 (Schering Corporation) proposed the construction of recombinant DNA vectors comprising a ds DNA sequence which codes for a variable region of a light or a heavy chain of an Ig specific for a predetermined ligand. The ds DNA sequence is provided with initiation and termination codons at its 5'- and 3'- termini respectively, but lacks any nucleotides coding for amino acids superfluous to the variable region. The ds DNA sequence is used to transform bacterial cells. The application does not contemplate the production of chimeric antibodies.

EP-A-1 102 634 (Takeda Chemical Industries Limited) describes the cloning and expression in bacterial host organisms of genes coding for the whole or a part of human IgE heavy chain polypeptide, but does not contemplate the production of chimeric antibodies.

EP-A- 0 125 023 (Genentech Inc. et al.), which was published after the priority date of the present

- 2 -

application, proposes the use of recombinant DNA techniques in bacterial cells to produce Ig's which are analogous to those normally found in vertebrate systems and to take advantage of the gene modification techniques proposed therein to construct chimeric Ig's or other modified form of Ig.

It is believed that the proposals set out in the above Genentech application did not lead to the expression of any significant quantities of Ig polypeptide chains, nor to the production of Ig activity, nor to the secretion and assembly of the chains into the desired chimeric Ig's.

The production of monoclonal antibodies was first disclosed by Kohler and Milstein (Kohler, G. and Milstein, C., Nature, 256, 495-497, 1975). Such monoclonal antibodies have found widespread use not only as diagnostic reagents (see, for example, 'Immunology for the 80s, Eds. Voller, A., Bartlett, A., and Bidwell, D., MTP Press, Lancaster, 1981) but also in therapy (see, for example, Ritz, J. and Schlossman, S.F., Blood, 59, 1-11, 1982).

The recent emergence of techniques allowing the stable introduction of Ig gene DNA into myeloma cells (see, for example, Oi, V.T., Morrison, S.L., Herzenberg, L.A. and Berg, P., PNAS USA, 80, 825-829, 1983; Neuberger, M.S., EMBO J., 2, 1373-1378, 1983; and Ochi, T., Hawley, R.G., Hawley, T., Schulman, M.J., Traunecker, A., Kohler, G. and Hozumi, N., PNAS USA, 80, 6351-6355, 1983), has opened up the possibility of using in vitro mutagenesis and DNA transfection to construct recombinant Ig's possessing novel properties.

- 3 -

However, it is known that the function of an Ig molecule is dependent on its three dimensional structure, which in turn is dependent on its primary amino acid sequence. Thus, changing the amino acid sequence of an Ig may adversely affect its activity. Moreover, a change in the DNA sequence coding for the Ig may affect the ability of the cell containing the DNA sequence to express, secrete or assemble the Ig.

It is therefore not at all clear that it will be possible to produce functional altered antibodies by recombinant DNA techniques.

Similar considerations apply to other proteins. It therefore cannot be expected that fusion of a gene coding for at least part of an Ig with a gene coding for at least part of another protein will lead expression of any protein, let alone expression of protein which can be secreted and assembled to give a functional chimeric antibody.

However, the present inventors have now discovered unexpectedly that it is possible to produce by recombinant DNA techniques secreted, assembled chimeric antibodies in which both parts of the protein are functional.

This surprising result is achieved by the use of the process of the present invention, which comprises:

- a) preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence comprising a first part which encodes at least the variable region of the heavy or light chain of an Ig molecule and a second part which encodes at least part of a second protein;

- 4 -

- b) if necessary, preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least the variable region of a complementary light or heavy chain respectively of an Ig molecule;
- c) transforming an immortalised mammalian cell line with the or both prepared vectors; and
- d) culturing said transformed cell line to produce a chimeric antibody.

The immortalised cell line is preferably of lymphoid origin, such as a myeloma, hybridoma, trioma or quadroma cell line. The cell line may also comprise a normal lymphoid cell, such as a B-cell, which has been immortalised by transformation with a virus, such as the Epstein-Barr virus. Most preferably, the immortalised cell line is a myeloma cell line or a derivative thereof.

It is known that some immortalised lymphoid cell lines, such as myeloma cell lines, in their normal state secrete isolated Ig light or heavy chains. If such a cell line is transformed with the vector prepared in step a) of the process of the invention, it will not be necessary to carry out step b) of the process, provided that the normally secreted chain is complementary to the part of the Ig molecule encoded by the first part of the vector prepared in step a).

However, where the immortalised cell line does not secrete or does not secrete a complementary chain, it will be necessary to carry out step b). This step may be carried out by further manipulating the vector produced in step a) so that this vector encodes not only the fusion of variable region and

second protein, but also the complementary variable region. However, preferably step b) is carried out by preparing a second vector which is used to transform the immortalised cell line.

The techniques by which such vectors can be produced and used to transform the immortalised cell lines are well known in the art, and do not form any part of the invention. However, they are well illustrated in the following Examples.

In the case where the immortalised cell line secretes a complementary light or heavy chain, the transformed cell line may be produced by transforming a suitable bacterial cell with the vector and then fusing the bacterial cell with the immortalised cell line, e.g. by Spheroplast fusion.

The first part of the DNA sequence may be joined directly to the second part thereof. Alternatively, the first part may be joined to the second part by an intervening sequence which encodes a specific cleavage sequence, for instance a Factor Xa cleavage sequence as described in our copending European patent application No. 85303414.8. Reference may be made to this application for further discussion of the use to specific cleavage sequences.

The second part of the DNA sequence may encode:

- i) at least part, for instance the constant region of a heavy chain, of an Ig molecule of different species, class or subclass;
- ii) at least the active portion or all of an enzyme;
- iii) a protein having a known binding specificity;

- 6 -

iv) a protein expressed by a known gene but whose sequence, function or antigenicity is not known; or

v) a protein toxin, such as ricin.

The chimeric antibody produced in case i) above will be of use in a number of applications. For instance, an established cell line may produce an Ig molecule having a useful specificity. However it may be of a class which is diagnostically or therapeutically undesirable, or it may not be secreted in useful quantities. For instance, Ig of class M is known to be difficult to use in rapid immunoassay techniques and is generally inconvenient for use in therapy, whereas Ig of class G can be readily used in these techniques. Therefore, it would be possible to produce a useful immunoassay reagent or therapeutic agent by replacing the IgM heavy chain constant region with an IgG heavy chain constant region. A particular example of such use would be in the production of a chimeric antibody having an anti Rh specificity, derived from an IgM secreting myeloma and IgG reactivity provided by an IgG derived heavy chain constant region.

Alternatively, the chimeric antibody could comprise an IgG derived variable region and an Ig E derived heavy chain constant region. Such a chimeric antibody could be used to investigate the action of IgE on mast cells, in diagnostic assays, for instance calibrating test procedures or, in therapy, to inhibit allergic reactions caused by the action of normal IgE molecules on mast cells.

In another alternative, the chimeric antibody may be used to alter the complement binding activity of an antibody, again by changing the heavy chain constant region.

In a further alternative, the chimeric

- 7 -

antibody may be constructed to resemble an (Fab')₂ fragment of a normal antibody.

The chimeric antibody produced in case ii) above may be used, in particular, in an enzyme linked immunoassay (ELISA) system, in place of the present use of separate antibodies and enzymes.

The chimeric antibody produced in case iii) above may also be used in immunoassays. For instance, the protein may have a binding specificity for an easily detectable label, such as a heavy or radioactive metal or a dyed or dyeable molecule. For instance, it would be possible to produce a divalent chimeric antibody having a different variable region at each end, the ends being connected by at least a part of a constant region.

The chimeric antibody produced in case iv) above may be used to investigate the products of known genes. For instance, it may be known that a particular gene produces a protein involved in the surface marking of a cell. However, the exact nature of the surface marker may not be known. The chimeric antibody produced in case iv) will comprise the protein product of the gene, which can therefore be more readily characterised. Moreover, antibodies to this gene product could be raised and used to investigate with certainty the distribution of the gene product on a cell surface.

The chimeric antibody produced in case v) above will clearly be of use in therapy, for instance as a targetted cytotoxic agent for cancer therapy. In this respect reference may be made to an article by Thorpe et al. (Thorpe, P.E., Edwards, D.C., Davies, A.J.S. and Ross, W.C.J., in 'Monoclonal Antibodies in Clinical Medicine', 167-201, Eds.,

- 8 -

McMichael, A.J. and Fabre, J.W., Academic Press, 1982).

The chimeric antibodies produced by the present process, especially where the DNA sequence encodes a specific cleavage site, may be used for purifying the second protein. For instance, the variable region may be made specific for a hapten which can be immobilised on a chromatography medium. The chimeric antibody can then be immobilised by affinity chromatography and contaminating material can be washed away. The second protein can then be cleaved from the variable region either before or after the variable region is eluted from the chromatography medium.

The chimeric proteins of the type referred to in cases ii) to iv) above and in the preceding paragraph also comprise aspects of the present invention.

The present invention is described in more detail, by way of non-limiting illustration only, with reference to the accompanying drawings; in which:

Figure 1A shows the structure of plasmid pSV-Vul;

Figure 1B shows the predicted structure of the IgM molecule produced by the J558L cell line transformed with the plasmid pSV-Vul;

Figure 2 shows polyacrylamide gels of the purified IgM molecule produced by the J558L cell line transformed with the plasmid pSV-Vul;

Figure 3A shows the structure to plasmid pSV-V_{NP}88;

Figure 3B shows the predicted structure of the F(ab)'₂ chimeric antibody produced by the J558L cell line transformed with the plasmid pSV-V_{NP}88;

- 9 -

Figure 4 shows polyacrylamide gels of purified products produced by the J558L cell line transformed with various plasmids;

Figure 5 shows polyacrylamide gels of purified products produced by the J558L cell line transformed with various plasmids in the presence or absence of tunicamycin;

Figure 6A shows the structure of plasmid pSV-V_{NP} γ SNase;

Figure 6B shows the predicted structure of the chimeric antibody produced by the J558L cell line transformed with the plasmid pSV-V_{NP} γ SNase;

Figure 7 shows polyacrylamide gels used for monitoring SNase activity;

Figure 8 shows an EISA-type assay;

Figure 9 shows the structure of plasmid pSV-V_{NP} γ myc;

Figure 10 shows an assay for c-myc antigenic determinant in Fab-myc;

Figure 11 shows the structure of plasmid pSV-V_{NP} H ;

Figure 12 shows a serological analysis of chimeric IgE by binding inhibition assays;

Figure 13 shows polyacrylamide gels of purified chimeric IgE;

Figure 14A shows the structure of plasmid pSV-V_{NP} γ Klenow;

Figure 14B shows the predicted structure of the Fab- γ Klenow chimeric antibody produced by the J558L cell line transformed with plasmid pSV-V_{NP} γ -Klenow;

Figure 15 shows polyacrylamide gels of the purified Fab- γ Klenow chimeric antibody; and

Figure 16 shows an assay for Klenow fragment activity.

- 10 -

In the drawings which show plasmids, thin horizontal lines depict pSV2 gpt vector, thick lines represent mouse or human Ig gene DNA, exons are represented by boxes, and hatched areas represent second (non-Ig) protein DNA.

The locations of the heavy chain locus transcription enhancer element (E) and the gpt gene are indicated. Restriction endonuclease cleavage sites are abbreviated as follows:

R = Eco RI; Xh = Xho I; S = Sac I; and Sl/Xh = a sequence formed by joining a Sal I site to an Xho I site. The sequence is presented around the Xho I site of plasmid pSV-V_{NP} γ SNase, which forms a junction of the γ 2b CH2 exon and the SNase gene.

In the diagrammatic representations of the predicted structures of Ig molecules and chimeric antibodies, disulphide linkages between heavy (H) and light (λ) chains are indicated by (-S-). Only one subunit of the decavalent pSV-V_{ul} encoded IgM is illustrated.

-11-

In the following Examples use is made of an established mouse plasmacytoma cell line J558L which secretes λ_1 light chains but does not produce any Ig heavy chain. This plasmacytoma cell line is described by Oi et al. (Oi, V.T., Morrison, S.L., Herzenberg, L.A., and Berg, P., PNAS USA, 80, 825-829, 1983).

In the Examples, reduced samples were analysed on 12% polyacrylamide gels, while unreduced samples were analysed on 7% polyacrylamide gels.

The Examples also use plasmid pSV-V μ 1 described by Neuberger, M.S., EMBO J., 2, 1373-1378, 1983. This plasmid comprises a complete mouse immunoglobulin μ gene cloned into the expression vector pSV2 gpt, and is shown in Figure 1A. The Ig μ polypeptide encoded by this plasmid has a heavy chain variable region, V H , characteristic of λ_1 light chain-bearing mouse antibodies which are specific for the hapten 4-hydroxy-3-nitrophenacetyl (NP): NP binding activity should therefore be formed following association of the pSV-V μ 1 encoded heavy chain with mouse λ_1 light chains.

To confirm this, pSV-V μ 1 DNA was introduced by spheroplast fusion into the J558L cell line and growth in selective medium essentially as described in the Neuberger article referred to above, except that HAT was omitted from the selective medium and mycophenolic acid was used at 5 μ g/ml, as described in the Oi et al. article referred to above. Cells were cloned by limiting dilution. Antibody samples were purified from supernatants of cloned J558L transfectants grown in Dulbecco's modified Eagle's medium containing 5% foetal calf serum. Supernatants (2 litres) were passed over 2ml columns of 4-hydroxy-5-iodo-3-nitrophenacetyl-amino-caproic acid Sepharose (NIPcap-Sepharose) and antibody eluted from the washed sorbent with 1mM NIPcapOH in phosphate buffered saline.

-12-

Biosynthetically labelled antibody was purified on 40 μ l NIPcap-Sepharose columns from supernatants of cells incubated for 4h at 37°C in medium containing L-[³⁵S]-methionine. Tunicamycin was, if required, included during the labelling and during a 2h preincubation at 8 μ g/ml (parallel incubations with an IgE secreting cell line confirmed the efficacy of this treatment).

Stably transfected cells were selected and cloned by limiting dilution. Twenty clones were analysed by radioimmunoassay and each secreted high levels of an NP-specific IgM antibody. As illustrated in Figure 2, homogeneous anti-NP IgM antibody can be purified from supernatants of pSV-V μ 1 transfected clones with a yield of about 3mg/ml.

In Figure 2 : lane (a) shows purified antibody (30 μ g) which has been boiled with 2-mercaptoethanol prior to electrophoresis and stained with Coomassie blue; and lane (b) shows markers to enable the molecular weight of the chains to be estimated. The predicted structure of the Ig molecule isolated from pV-V μ 1 transfected clones is shown in Figure 1B.

Example 1 - F(ab)'₂ - like chimeric antibody

A derivative of pSV-V μ 1 was constructed in which the C μ exons were replaced by the CH1 and hinge exons of the mouse γ 2b gene. To provide translation termination and polyadenylation sequences, an exon, C δ s, derived from the gene encoding secreted mouse δ chains was placed at the 3' end of the gene. The constructed plasmid pSV-V μ NP $\gamma\delta$ is shown in Figure 3A.

To construct plasmid pSV-V μ NP $\gamma\delta$, the V μ NP exons from pSV-V μ 1 contained on a common Eco RI fragment are placed in a vector consisting of the Bam HI - Eco RI fragment of pSV2gpt (see Mulligan, R.C. and Berg, P., PNAS USA, 78, 2072-2076, 1981) with an Xho I adapter in the Bam HI

-13-

site. The plasmid contains an Eco RI - Sac I mouse C χ 2b fragment derived from phage λ MYG9 (see Neuberger, M.S. and Calabi, F., Nature, 305, 240-243, 1983). The mouse C δ _s exon as the PSV-V_{NP} χ δ plasmid is contained in a Bam HI fragment of phage Ch 257 3 (see Cheng, H. - L., Blattner, F. R., Fitzmaurice, L., Mushinski, J.F., and Tucker, P.W., Nature, 296, 410-415, 1982) which was obtained as a Sac I - Sal I fragment after cloning in M13mp 11.

The truncated heavy chain gene of plasmid pSV-V_{NP} χ δ would be expected to direct the synthesis of a F(ab)'₂ - like chimeric antibody, as shown diagrammatically in Figure 3B, consisting of two IgG2b Fab molecules disulphide linked together through the χ 2b hinge with a 21 amino acid tail piece at the carboxy terminus encoded by the C δ _s exon.

Plasmid pSV-V_{NP} χ δ was transfected into J558L cells and radioimmunoassay revealed that stably transfected cells secreted high levels of λ ₁-bearing anti-NP antibody. This NP-specific antibody was purified from culture supernatants of several transfected clones with a yield of 5 to 10mg/l. Polyacrylamide gel electrophoresis of the purified material (Figure 4) shows that the major protein species has an unreduced molecular weight of about 110,000 daltons. After reduction, a band comigrating with λ light chain as well as several higher molecular weight polypeptides are observed. The most abundant of these larger polypeptides has a molecular weight of 31,000 and would constitute the heavy chain of the F(ab)'₂ like antibody. However, there is clear contamination of the pSV-V_{NP} χ δ F(ab)'₂ antibody with other NP-binding material that has an unreduced molecular weight of around 50,000 daltons and is composed of λ ₁ light chains and one of several heavy chains in the molecular weight range 36,000 to 40,000. The presence

-14-

of this minor antibody component does not reflect glycosylation heterogeneity as the electrophoretic mobility of the pSV-V_{NP} $\delta\delta$ encoded anti-NP antibody is unaffected by inclusion of tunicamycin in the incubation medium during biosynthetic labelling experiments (Figure 5). It is likely that the minor bands differ from the F(ab)'₂ antibody in the carboxy terminal portion of the heavy chain, possibly as a result of alternative processing of pSV-V_{NP} $\delta\delta$ immunoglobulin gene RNA transcripts. Nevertheless, despite the contaminating bands, it is clear that F(ab)'₂-like anti-NP antibody can be synthesized and secreted in good yield by pSV-V_{NP} $\delta\delta$ transfected J558L cells.

Example 2- Fab-nuclease chimeric antibody

A DNA restriction fragment containing the S. aureus nuclease (SNase) gene was inserted into the Xho I site located in the CH2 exon of the mouse δ 2b gene. Plasmid pSV-V_{NP} SNase was assembled by inserting the V_{NP} exons contained on the common Eco RI fragment into the vector comprising the Bam HI - Eco RI fragment of pSV2gpt with an Xho I adapter in the Bam HI site as described in Example 1. An Eco RI - Xho I mouse C δ 2b fragment derived from phage λ MYG9 was also inserted in the vector, so that pSV-V_{NP} δ SNase contains the δ 2b CH1, hinge and 5' end of the CH2 exons. The SNase coding region is derived from an M13mp8 clone containing an S. aureus Sau 3A fragment in the Bam HI site. Removal of the SNase gene from M13mp8 as a Bam - Sal I fragment and recloning in M13mpl2W (see Karn, J., Mathes, H. W. D., Gait, M. J., and Brenner, S., Gene, 32, 217-224, 1984) allowed its isolation as an Xho I - Sal I fragment for final assembly of the pSV-V_{NP} SNase, the structure of which is shown in Figure 6A.

The heavy chain gene of pSV-V_{NP} δ SNase is similar to that of pSV-V_{NP} $\delta\delta$ except that the C δ _S exon has been removed and replaced by an exon containing the first four

-15-

codons of the χ 2b CH2 exon fused in phase to the nuclease coding region. SV40-derived sequences of the pSV2gpt-derived vector provide polyadenylation signals.

J558L cells were transfected with pSV-V_{NP} χ SNase and cells surviving in selective medium were cloned by limiting dilution. Radioimmunoassay of supernatants of cloned transfectants revealed that about one third were positive for the production of λ -bearing anti-NP antibody. Positive clones yielded between 1 mg/l and 10 mg/l of NP binding antibody, which has the predicted structure shown in Figure 6B.

Analysis of biosynthetically labelled antibody by gel electrophoresis reveals a band comigrating with λ_1 light chain as well as two heavy chain bands of molecular weight 45,000 and 46,000 (Figure 5). The difference between these two heavy chains has not been identified but their mobilities agree well with the predicted mobility of the V_{NP} χ SNase heavy chain. Although the sequence Asn-Asn-Thr is present in SNase, the two V_{NP} χ SNase heavy chain bands are still present in samples purified from supernatants of cells that have been biosynthetically labelled in the presence of tunicamycin (Figure 5). This demonstrates that the difference between the two pSV-V_{NP} χ SNase heavy chains is not due to N-linked glycosylation. The V_{NP} χ SNase antibody appears somewhat more heterogenous on a non-reduced gel, giving bands with the expected mobilities of both the F(ab)'₂-SNase and Fab-SNase (Figure 4). The presence of SNase on the heavy chain carboxy terminus might inhibit disulphide linking of the χ 2b hinge regions.

To test for nuclease activity in the V_{NP} χ SNase preparation, samples which had been purified on hapten-Sepharose columns were incubated with single stranded DNA substrate. Digestion of the DNA was monitored following agarose gel electrophoresis as

-16-

follows. Single stranded M13DNA (2 μ g) was incubated at 37°C for 30 minutes in 25 mM sodium borate, 250 mM NaCl, 10mM CaCl₂, PH 8.5 (20 μ l) containing varying amounts of V_{NP} γ SNase chimeric antibody or of purified S. aureus nuclease. The quantities of antibody/enzyme used are given in nanograms. DNA in the samples was then analysed by ethidium bromide fluorescence after electrophoresis through a 1.2% agarose gel. A Hind III digest of phage DNA provides size markers. Ca⁺⁺ dependency of the nuclease activity was confirmed by running incubations in the presence of 40mM MgCl₂, 25mM EGTA.

As shown in Figure 7, V_{NP} γ SNase but not V_{NP} δ antibodies show nuclease activity and this activity - like that of authentic S. aureus nuclease - is dependent on Ca⁺⁺ but not Mg⁺⁺ ions. As judged on a molar basis, the catalytic activity of the V_{NP} γ SNase sample is about 10% that of authentic S.aureus nuclease.

The V_{NP} γ SNase chimeric antibody can be used as a genetically conjugated enzyme linked antibody in ELISA-type assays as shown in Figure 8. Antigen coated plastic plates were incubated with various amounts of V_{NP} γ SNase protein and bound antibody was then detected by virtue of its nuclease activity. This was achieved by addition to the plate of a solution containing DNA and ethidium bromide. Following digestion of the DNA substrate by the immobilized V_{NP} γ SNase antibody, the fluorescence due to the DNA/ethidium bromide complex substantially decreased.

In particular, polyvinyl microtitre plates were coated with (NIP)₂₀ - bovine serum albumin (40 μ g ml). After blocking unreacted sites with BSA, dilutions of V_{NP} γ SNase or V_{NP} δ chimeric antibodies were incubated in the wells, the amounts of antibody being given in nanograms in Figure 8. After washing off unbound material, a solution (40 μ l) containing 1 μ g M13 single

-17-

stranded DNA and $\mu\text{g/ml}$ ethidium bromide in pH 8.5 buffer was added. The plate was photographed after a 1 hour incubation at 37°C .

As shown in Figure 8, quantities in the range of 10 ng of V_{NP} δ SNase antibody are easily detected and no decrease in fluorescence is obtained with the V_{NP} $\delta\delta$ antibody control. We have found that the assay may be made at least tenfold more sensitive by increasing the incubation time with the DNA substrate.

Example 3 - Fab-myc chimeric antibody

The carboxyterminal portion of the mouse c-myc gene was fused to the antibody Fab. The product of the c-myc gene is a protein which contains many thiol groups and is normally resident within the cell. There is no reason to believe that the third exon of c-myc on its own will encode a functional protein domain. Thus, if the Fab-myc fusion protein were secreted from the cell it would provide a source of protein for making anti-myc antisera.

Plasmid pSV- V_{NP} δ myc was assembled essentially as described for the assembly of pSV- V_{NP} $\delta\delta$ except that the pSV- V_{NP} $\delta\delta$ Sac I - Xho I fragment containing the $C\delta_s$ exon was replaced by a Sac I - Bgl II fragment containing the 3' exon of mouse c-myc. The restriction site in Figure 9 marked Bg/B is a site formed by joining the Bgl II site at the 3' end of c-myc to the Bam HI site of pSV2gpt. The c-myc fragment comes from phage λ MYG2, which contains the translocated c-myc gene of mouse plasmacytoma X63Ag8 (see Neuberger and Calabi, loc. cit.).

The plasmid is similar in structure to pSV- V_{NP} $\delta\delta$ except that the $C\delta_s$ exon is replaced with the 3'-terminal exon of the mouse c-myc gene. This c-myc exon encodes 187 aminoacids (see Bernard, O., Cory, S., Gerondatis, S., Webb, E. and Adams, J. M., EMBO J., 2375-2383, 1983) and should provide the transcription polyadenylation signal.

-18-

The plasmid was transfected into J558L and cells from wells positive for production of anti-NP antibody cloned by limiting dilution. Hapten-binding protein was purified from culture supernatants and analyzed for the presence of c-myc antigenic determinants in an indirect radioimmunoassay.

Samples of either the putative Fab-myc or of the anti-NP F(ab)'₂ (to act as control) were incubated in wells of a polyvinyl microtitre plate that had been coated with a monoclonal anti-c-myc antibody; bound anti-NP antibody was then detected using a radioiodinated monoclonal anti-idiotope antibody which recognises the Fab portion of the anti-NP antibodies.

As shown in Figure 10, the Fab-myc clearly binds to the monoclonal anti-c-myc antibody, whereas the anti-NP F(ab)'₂ and other controls do not. The Fab-myc was also recognized by two other monoclonal antibodies that are specific for the carboxyterminal end of c-myc. SDS/polyacrylamide gel electrophoresis of the Fab-myc reveals that it is somewhat heterogenous; a band comigrating with λ_1 light chains and several bands with higher molecular weight in the range 38,000 to 55,000 daltons are observed, without a single dominant heavy chain band being apparent. The expected size of the Fab-myc is 50,000 daltons. It has been observed that, after prolonged storage, precipitates appear in the Fab-myc sample and SDS/polyacrylamide gel electrophoresis reveals more extensive heterogeneity of the heavy chain bands. We therefore believe that the heterogeneity of the Fab-myc protein indicated by the SDS/polyacrylamide gel analysis is most probably due to proteolytic degradation.

Example 4 - Chimeric Mouse - Human Antibodies.

A plasmid pSV-V_{NP}H_E was constructed as follows. The Eco RI - Bam HI fragment of plasmid pSV-V_{pl} was

-19-

cloned between the Eco RI and Bam HI sites of plasmid pSV2gpt to yield pSV-V_{NP}. The Bam HI fragment of phage λ E1.2 (see Flanagan, J. G. and Rabbitts, T. H., EMBO J., 1, 655-660, 1982), which includes exons C ϵ 1 to C ϵ 4 of the human ϵ gene was cloned into pSV-V_{NP} and the plasmid pSV-V_{NP}H ϵ completed by including in its unique Eco RI site the Xba I - Eco RI enhancer-containing fragment of the mouse heavy chain locus.

The structure of the pSV-V_{NP}H ϵ plasmid is shown in Figure 11 and encodes for a heavy chain comprising a mouse variable region and a human ϵ constant region.

pSV-V_{NP}H ϵ was introduced into J558 cells by spheroplast fusion, and stably transfected clones were selected as described above. Transfectants were obtained with a frequency of between 10^{-3} and 10^{-4} . Culture supernatants were assayed for production of λ 1 - bearing anti-NP antibodies by radioimmunoassay as described above. Between 50 and 80% of the clones were positive. Antibody was purified from culture supernatants of several transfected clones by affinity chromatography as described above, with yield of about 2mg per litre.

Binding inhibition assays were used to demonstrate that the purified chimeric antibody displayed human antigenic determinants (Figure 12).

Assays were performed in which the binding of a radioiodinated human myeloma IgE to either a monoclonal (a) or polyclonal (b) anti-human ϵ antiserum was inhibited by various concentrations of unlabelled chimeric IgE (●) of unlabelled myeloma IgE (■).

Wells of a Dynatec microtitre plate were coated with a solution containing either $1 \mu\text{g} \cdot \text{ml}^{-1}$ of a monoclonal mouse anti-human ϵ antibody (antibody RB6-2; given by M. D. Cooper) or $3 \mu\text{g} \cdot \text{ml}^{-1}$ of a polyclonal sheep anti-human ϵ antiserum (Seward Laboratory). After blocking of unreacted sites with bovine serum albumin, a human

-20-

myeloma IgE (Serotec) that had been radiolabelled with ^{125}I was incubated in the wells in the presence of different concentrations of either chimeric IgE or unlabelled myeloma IgE itself.

The affinity-purified chimeric antibody competes with the binding of radiolabelled human myeloma IgE to both monoclonal (Figure 12A) and polyspecific (Figure 12B) anti- ϵ antisera. Furthermore, binding of radiolabelled myeloma IgE to the anti- ϵ antiserum was inhibited completely (Figure 12B), indicating that the chimeric antibody displays all the ϵ antigenic determinants recognised by this polyclonal antiserum. The chimeric antibody competed with the binding of the radiolabelled myeloma IgE to the anti- ϵ antisera better than did the unlabelled myeloma IgE itself, probably because the purified chimeric antibody is essentially homogenous (see Figure 13), whereas the commercial sample of myeloma IgE is not.

The structure of the chimeric protein was investigated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Examination of reduced anti-NP IgE reveals a band comigrating with mouse $\lambda 1$ light chains and a diffuse heavy-chain band of relative molecular mass (M_r) $\sim 72,000$ (72K) (Figure 13A); this is considerably larger than the M_r of the ϵ polypeptide chain as predicted from the DNA sequence. However, this discrepancy is resolved by SDS-PAGE of biosynthetically labelled anti-NP IgE secreted by cells labelled in the presence of tunicamycin (Figure 13B). Incubation with this glycosylation inhibitor reduces the apparent relative molecular mass of the secreted anti-NP IgE from 72K to the predicted value of 62K. Thus, the chimeric IgE, like IgE from human myeloma, is heavily glycosylated. The electrophoretic mobility of unreduced anti-NP IgE in SDS polyacrylamide gels is consistent with

-21-

it having an $\epsilon_2\lambda_2$ structure.

Figure 13A shows the SDS-PAGE results obtained from purified antibody (30 μ g) from a cloned pSV-V_{NP}HE transfectant of J558L (JW8/5/13) which was boiled in the presence of 2-mercaptoethanol, subjected to electrophoresis through a 9% gel and stained with Coomassie blue. In Figure 13B, the results are shown for biosynthetically labelled antibody from either J558L or the transfectant JW8/5/13 which was purified on NIP-Sepharose columns and analysed on a 7% gel after reduction. Samples purified from cells labelled in the presence of tunicamycin are marked +Tm. The positions of relative molecular mass markers are indicated (94K = relative molecular mass 94,000). Biosynthetic labelling with [L-³⁵S] methionine and purification of both labelled and unlabelled samples on hapten-Sepharose columns were performed as described above.

Two types of assay were performed to determine whether the chimeric anti-NP IgE antibody exhibits the physiological effector functions of authentic human IgE. In one type of assay, the ability of the antibody to trigger histamine release from human basophils was tested. A preparation of mononuclear cells from peripheral blood containing 1-2% basophils was passively sensitized with the chimeric antibody before incubation with hapten (5-iodo-4-hydroxy-3-nitrophenacetyl caproate, NIP) coupled to bovine serum albumin (NIP-BSA). The results (Table 1) indicate that, after preincubation of basophils with the chimeric IgE, NIP-BSA is able to trigger a dose-dependent release of histamine. A heterologous antigen, antigen P1 of the house dust mite Dermatophagoides pteronyssinus, failed to induce histamine release. Similarly, only background levels of histamine release were obtained with either the chimeric antibody or NIP-BSA alone. These results indicate that

-22-

the anti-NP IgE, like authentic human IgE, will not cause degranulation by itself, but will trigger histamine release following crosslinking with antigen.

In a second assay, it was demonstrated that incubation with anti-NP IgE could also block the subsequent passive sensitization of basophils by atopic sera containing high IgE levels. Table 2 shows that house dust mite antigen P1 can induce the release of histamine from basophils preincubated with serum containing anti-P1 IgE antibody. However, this same serum failed to effect histamine release when the cells had been incubated previously with the chimeric antibody at concentrations $>0.1 \mu\text{g ml}^{-1}$.

The results described here demonstrate that transfection of DNA into mouse myeloma cells is an effective way of producing large amounts of chimeric antibodies in which mouse V regions provide antigen-binding specificity and human C_H regions provide human effector functions. The known antigen-binding specificity of such an antibody makes its purification extremely simple. Production of a chimeric IgE in this way has proved particularly attractive as no monoclonal human IgE of known antigen specificity was previously available. The chimeric antibody may, therefore, prove useful in routine clinical assays. It has been demonstrated that this monoclonal IgE is able to block the release of histamine from human basophils which can be triggered in vitro by sera from allergic subjects. It will clearly be important to discover whether analogous blocking can be achieved in vivo using skin sensitization assays.

-23-

Table 1 Histamine release triggered from human basophils passively sensitized with chimeric IgE

Antigen	% Histamine release (\pm s.e.m.)
-	6.4 \pm 0.8
10 μ g ml ⁻¹ NIP-BSA	18.4 \pm 2.4
1 μ g ml ⁻¹ NIP-BSA	36.0 \pm 5.6
0.1 μ g ml ⁻¹ NIP-BSA	31.2 \pm 12.0
0.01 μ g ml ⁻¹ NIP-BSA	26.4 \pm 2.4
0.001 μ g ml ⁻¹ NIP-BSA	7.2 \pm 1.6
0.0001 μ g ml ⁻¹ NIP-BSA	5.2 \pm 1.2
20 μ g ml ⁻¹ Antigen P1	4.5 \pm 0*

Mononuclear cells were prepared from peripheral blood by sedimentation through dextran-EDTA; these preparations contained 1-2% basophils. Cells were incubated in duplicate at 37°C for 2 h in complete Tyrode's buffer with 1.5 μ g ml⁻¹ chimeric anti-NP IgE. Cells were then centrifuged and resuspended in complete Tyrode's buffer containing the indicated concentrations of (NIP)₃₀-BSA. After 15 min, the histamine released into the supernatant was extracted and assayed fluorimetrically. The maximum histamine release that could be obtained by incubating the cells at 100°C was 62.5 ng ml⁻¹. The results are expressed as percentage histamine release; (antigen-induced histamine release [ng ml⁻¹]) \times 100/maximum histamine release obtainable (ng ml⁻¹). The mean background percentage release obtained in repeated experiments was 6.0 \pm 2.5. Both NIP-BSA (1.0 μ g ml⁻¹) and antigen P1 (20 μ g ml⁻¹) alone repeatedly failed to induce histamine release above background levels.

*Data obtained in a separate experiment using cells from the same donor.

-24-

Table 2 Blocking of histamine release by preincubation
with chimeric IgE

Concentration ($\mu\text{g ml}^{-1}$) of chimeric anti-NP IgE in preincubation	Serum from allergic subject	Antigen P1	% Histamine release (\pm s.e.m.)
-	+	+	20.5 \pm 2.7
0.01	+	+	16.9 \pm 2.4
0.1	+	+	7.2 \pm 0
1	+	+	8.2 \pm 1.0
10	+	+	7.2 \pm 1.0
10	-	-	8.4 \pm 1.2
-	-	+	7.5 \pm 1.7

Mononuclear cells were prepared as described in Table 1. A 2-h incubation with different concentrations of chimeric anti-NP IgE was followed by a 2-h incubation with allergic serum (diluted 1:30 in complete Tyrode's), prior to a 15-min exposure to antigen P1 ($20\mu\text{g ml}^{-1}$). The allergic serum used had a total IgE level of 4,800IU ml^{-1} , and 1,600 BA units ml^{-1} of IgE specific for D. pteronyssinus antigen P1. The maximum histamine release obtained by incubating the cells used in this experiment at 100°C was 10.4 ng ml^{-1} .

-25-

Example 4 - Fab- γ - Klenow Chimeric Antibody.

A plasmid, pSV-V_{NP} γ Klenow, which encodes the heavy chain of a recombinant antibody in which the Klenow fragment of DNA polymerase I is fused to the Fab portion of a mouse IgG2b molecule, was assembled.

The construction of pSV-V_{NP} γ Klenow is analogous to that previously described for pSV-V_{NP} γ SNase. The coding region for the Klenow fragment of DNA polymerase I was obtained as a BamHI fragment by combining two plasmids, pCJ14 (C.M. Joyce and N.G.D. Grindley, PNAS USA. 80, 1830-1834, 1983) and pCJ89 (C.M. Joyce and N.G.D. Grindley, J. Bacteriol., 158, 636-643, 1984), in which BamHI linkers have been inserted on either side of the Klenow coding region. This BamHI fragment was converted into a SalI fragment by use of linkers and inserted into the unique XhoI site of pSV-V_{NP} γ 2b (CH2, CH3).

This antibody/enzyme fusion gene contains a variable region, V_{NP}, such that association of the pSV-V_{NP} γ Klenow heavy chain with the mouse immunoglobulin λ light chain from the J558L cell line will form a binding site for the hapten 4-hydroxy-3-nitrophenacetyl (NP). The V_{NP} gene is linked to exons encoding the CH1, hinge and aminoterminal part of the CH2 domain of a mouse immunoglobulin γ 2b heavy chain. The DNA encoding the rest of CH2 and all of CH3 has been replaced by a fragment of the E. coli DNA polymerase I gene that specifies the 5'-3' polymerase and 3'-5' exonuclease activities (the Klenow fragment). This Fab-Klenow fusion gene was cloned into the plasmid vector pSV2gpt which provides a polyadenylation signal for the Fab-Klenow transcription unit and also provides a marker, gpt, that confers resistance to the drug mycophenolic acid and thus allows selection of stably transfected mammalian cells.

Spheroplast fusion was used as a means to introduce

-26-

psv-V_{NP} Klenow DNA into J558L cells. (The procedure used for protoplast fusion and selection of transfected clones is described in detail by M. S. Neuberger and G. T. Williams in Protein engineering : applications in science, medicine and industry (M. Inouye and R. Sarma, eds.), Academic Press,) Stable transfectants were selected in medium containing mycophenolic acid and the presence of NP-specific antibody in the culture medium of such transfectants was identified by radioimmunoassay. The transfectants were cloned by limiting dilution and one particular clone, JW64/7, that gave a high antibody titre was chosen for further study.

The protein secreted by JW64/7 was examined by SDS/polyacrylamide gel electrophoresis of biosynthetically labelled samples that had been purified on hapten-Sepharose sorbent (Figure 15B). As expected from the predicted structure of the Fab-Klenow protein (Figure 14B), the gel reveals the presence of two polypeptide chains: a band corresponding to λ_1 light chain and a heavy chain of mol. wt. about 96,000 (Figure 15B). Within the Klenow portion of the Fab-Klenow heavy chain, four sequences of the form Asn-X-Thr/Ser are encountered; these might constitute sites for N-linked glycosylation. In order to discover whether the Fab-Klenow heavy chain is in fact glycosylated, biosynthetic labelling experiments were performed in the presence of the glycosylation inhibitor tunicamycin. The results (Figure 15B) reveal that tunicamycin does indeed result in the synthesis of a heavy chain of reduced molecular weight.

Fab-Klenow protein was purified by affinity chromatography on NP-Sepharose from culture supernatant of JW64/7 grown in DMEM/10% foetal calf serum, giving a homogeneous preparation (Figure 15A). The yield varied in the range of 1 to 15 mg of protein per litre of culture supernatant. The 5'-3' polymerase activity of

-27-

the purified protein was measured using the classical assay (The assay was performed as described by P. Setlow, Methods Enzymol. 29, 3-12, 1974.) in which the enzyme is incubated with "activated" DNA and the four dNTPs, one of which is radiolabelled; the incorporation of radioactivity into acid-precipitable material is followed. In this assay, using activated calf thymus DNA as substrate, the Fab-Klenow gave an activity of about 1.1×10^3 units/mg as compared to a value of 7×10^3 units/mg obtained under the same assay conditions using a commercial sample of homogeneous Klenow fragment which had been prepared by proteolytic fragmentation of DNA polymerase I purified from E. coli. A decreased specific activity (expressed as units per mg protein) of the Fab-Klenow compared to the normal enzyme is to be expected in view of their different molecular weights. However, this can only account for part of the difference in activity. Examination of unreduced Fab-Klenow in SDS/polacrylamide gels (not shown) suggests the presence of divalent $F(ab')_2$ -Klenow as well as monovalent protein. It is possible that the $F(ab')_2$ -Klenow might only show half-site reactivity; alternatively, it might be that glycosylation reduces the specific activity of the Fab-Klenow.

A major use of DNA polymerase I Klenow fragment is in the chain termination of DNA sequencing. As shown in Figure 16, Fab-Klenow can indeed be used successfully for this purpose. Figure 16 shows the use of Fab-Klenow in chain termination DNA sequencing. DNA from an M13 clone was sequenced using Fab-Klenow as described by Sanger et al. (F. Sanger, S. Nicklen and A. R. Coulson, PNAS USA, 74, 5463-5476, 1977) using 1 unit per clone of Fab-Klenow.

Thus it has been shown that recombinant antibody technology can usefully be applied to the tagging of specific enzymes such that they are secreted from the

-28-

cell and can be readily purified to homogeneity in a one step purification.

CONCLUSION

The above Examples demonstrate that by using the process of the present invention, it is possible to produce secreted, functional chimeric antibodies, which was not previously possible. The process enables the production of a number of chimeric antibodies which have not previously been known.

CLAIMS

1. A process for the production of a chimeric antibody, comprising:
 - a) preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence comprising a first part which encodes at least the variable region of the heavy or light chain of an Ig molecule and a second part which encodes at least part of a second protein;
 - b) if necessary, preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least the variable region of a complementary light or heavy chain respectively of an Ig molecule;
 - c) transforming an immortalised mammalian cell line with the or both prepared vectors; and
 - d) culturing said transformed cell line to produce the chimeric antibody.
2. The method of claim 1, wherein the immortalised cell line is of myeloid origin.
3. The method of claim 2, wherein the immortalised cell line is a myeloma cell line or derivative thereof.
4. The method of any one of claims 1 to 3, wherein the immortalised cell line secretes a complementary light or heavy chain respectively, whereby step b) is omitted.
5. The method of any one of claims 1 to 3, wherein step b) is carried out by preparing a separate vector which is transformed into the immortalised cell line with the vector prepared in step a).
6. The method of any one of claims 1 to 3, wherein step b) is carried out by further manipulation of the vector prepared in step a).

7. The method of any one of claims 1 to 4, wherein the immortalised cell line secretes a complementary light or heavy chain respectively, and the transformation is accomplished by transforming a suitable bacterial cell with the vector prepared in step a) and then fusing the bacterial cell with the immortalised cell line.
8. The method of any one of claims 1 to 7, wherein the first part of the DNA sequence of the vector prepared in step a) is directly linked to the second part.
9. The method of any one of claims 1 to 7, wherein the first part of the DNA sequence of the vector prepared in step a) is linked to the second part by an intervening sequence which encodes a specific cleavage sequence.
10. The method of claim 9, wherein the cleavage sequence is specific for Factor Xa.
11. A chimeric antibody comprising an antigen binding region having a known specificity and of a first class linked to at least part of a constant region derived from at least one Ig molecule of a different species, class or subclass.
12. The chimeric antibody of claim 11, which is a F(ab)'₂-type antibody.
13. The chimeric antibody of claim 11, wherein the variable region is derived from a mouse antibody specific for NP and the constant region is a human CE region.
14. A chimeric antibody comprising an antigen binding region linked to at least a part of an enzyme.
15. A chimeric antibody comprising an antigen binding region linked to a protein having a known binding specificity.

-32-

16. A chimeric antibody comprising an antigen binding region linked to a protein expressed by a known gene.
17. A chimeric antibody comprising an antigen binding region linked to a protein toxin.
18. The chimeric antibody of any one of claims 11 to 17 wherein the antigen binding region is connected to the second protein by a specifically cleavable linker sequence.
19. Use of the chimeric antibody of claim 14 in an ELISA-type assay.
20. Use of the chimeric antibody of claim 15 in an immunoassay.
21. The chimeric antibody of claim 17 for use in therapy.
22. Use of the chimeric antibody of claim 18 in the purification by affinity chromatography of the second protein.
23. The plasmid pSV-V_{NP} γ δ .
24. The plasmid pSV-V_{NP} γ SNase.
25. The plasmid pSV-V_{NP} γ myc.
26. The plasmid pSV-V_{NP} HE.
27. The plasmid pSV-V_{NP} γ Klenow.
28. J558L cells transformed with any one of the plasmids of claims 23 to 27.
29. The chimeric antibody produced by culturing any one of transformed J558L cells of claim 28.

FIG. 1B






FIG. 3B

FIG. 1A

pSV - V μ 1



pSV - V_{NP} $\gamma\delta$




FIG. 3A

SUBSTITUTE SHEET




FIG. 4




FIG. 5




FIG. 2

3/10






FIG. 6B

FIG. 6A

$$pSV - V_{NP} \gamma SNase$$


4/10

FIG. 7



SUBSTITUTE SHEET

5/10




FIG. 8

SUBSTITUTE SHEET

6/10

FIG. 9



pSV - V_{NP}γmyc

FIG. 10

SUBSTITUTE SHEET

7/10




FIG. 11





FIG. 13

SUBSTITUTE SHEET

8/10



SUBSTITUTE SHEET

FIG. 12

9/10

pSV-V_{NP}γ Klenow

FIG. 14 A.







FIG. 14 B.

10/10



SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 85/00392

I. CLASSIFICATION F SUBJECT MATTER (If several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁴ : C 12 N 15/00; C 07 K 15/00; A 61 K 39/395; C 07 K 3/18; C 12 N 5/00; C 12 P 21/00; G 01 N 33/563																																
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">IPC⁴</td> <td style="border: 1px solid black; padding: 5px;">C 12 N; C 12 P</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *</div>			Classification System	Classification Symbols	IPC ⁴	C 12 N; C 12 P																										
Classification System	Classification Symbols																															
IPC ⁴	C 12 N; C 12 P																															
III. DOCUMENTS CONSIDERED TO BE RELEVANT* <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; padding: 5px;">Category *</th> <th style="width: 60%; padding: 5px;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%; padding: 5px;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">EP, A, 0068763 (THE BOARD OF REGENTS UNIVERSITY TEXAS SYSTEM) 5 January 1983, see claims 1-15</td> <td style="text-align: center; vertical-align: top; padding: 5px;">15</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="text-align: center; vertical-align: top; padding: 5px;">--</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">Chemical Abstracts, volume 95, no.4, 27 July 1981, Columbus, Ohio (US) V. Raso et al.: "Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells", see page 363, abstract 30711m, & Cancer Res. 1981, 41(6) 2073-8 (Eng.)</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1, 17</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="text-align: center; vertical-align: top; padding: 5px;">--</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">EP, A, 0105521 (TAKEDA) 18 April 1984, see claims 1-15</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="text-align: center; vertical-align: top; padding: 5px;">--</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">WO, A, 83/03971 (PRESIDENT AND FELLOWS OF HARVARD COLLEGE) 24 November 1983, see claims 1-13; pages 4-8</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="text-align: center; vertical-align: top; padding: 5px;">--</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">EP, A, 0090898 (GENETIC SYSTEMS CORP.) 12 October 1983, see claims 1-10</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> </tbody> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	EP, A, 0068763 (THE BOARD OF REGENTS UNIVERSITY TEXAS SYSTEM) 5 January 1983, see claims 1-15	15	A	--	1	A	Chemical Abstracts, volume 95, no.4, 27 July 1981, Columbus, Ohio (US) V. Raso et al.: "Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells", see page 363, abstract 30711m, & Cancer Res. 1981, 41(6) 2073-8 (Eng.)	1, 17	Y	--	1	Y	EP, A, 0105521 (TAKEDA) 18 April 1984, see claims 1-15	1	Y	--	1	A	WO, A, 83/03971 (PRESIDENT AND FELLOWS OF HARVARD COLLEGE) 24 November 1983, see claims 1-13; pages 4-8	1	A	--	1	A	EP, A, 0090898 (GENETIC SYSTEMS CORP.) 12 October 1983, see claims 1-10	1
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																														
X	EP, A, 0068763 (THE BOARD OF REGENTS UNIVERSITY TEXAS SYSTEM) 5 January 1983, see claims 1-15	15																														
A	--	1																														
A	Chemical Abstracts, volume 95, no.4, 27 July 1981, Columbus, Ohio (US) V. Raso et al.: "Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells", see page 363, abstract 30711m, & Cancer Res. 1981, 41(6) 2073-8 (Eng.)	1, 17																														
Y	--	1																														
Y	EP, A, 0105521 (TAKEDA) 18 April 1984, see claims 1-15	1																														
Y	--	1																														
A	WO, A, 83/03971 (PRESIDENT AND FELLOWS OF HARVARD COLLEGE) 24 November 1983, see claims 1-13; pages 4-8	1																														
A	--	1																														
A	EP, A, 0090898 (GENETIC SYSTEMS CORP.) 12 October 1983, see claims 1-10	1																														
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>																																
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">6th December 1985</td> <td style="border-bottom: 1px solid black; padding: 5px;">20 DEC. 1985</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">International Searching Authority</td> <td style="border-bottom: 1px solid black; padding: 5px;">Signature of Authorized Officer</td> </tr> <tr> <td style="padding: 5px;">EUROPEAN PATENT OFFICE</td> <td style="padding: 5px;"> G.L.M. Kruidenberg </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	6th December 1985	20 DEC. 1985	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	 G.L.M. Kruidenberg																						
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																															
6th December 1985	20 DEC. 1985																															
International Searching Authority	Signature of Authorized Officer																															
EUROPEAN PATENT OFFICE	 G.L.M. Kruidenberg																															

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category*	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
P,X	Nature, 314, no. 6010, April 1985 London (GB) Shun-Ichi Takeda et al.: "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", pages 452-454, see the whole article --	1,11,12
P,X	Nature 314, no. 6008, 21st March 1985 London (GB) M. Neuberger et al.: "A hapten-specific chimaeric Ig E antibody with human physiological effector function", pages 268-270, see the whole article --	1-12
P,X	Nature 312, no. 5995, December 1984 London (GB) G. Boulianne et al.: "Production of functional chimaeric mouse/human antibody", pages 643-646, see the whole article --	1,11,12
P,X	Nature 312, no. 5995, December 1984 London (GB) M. Neuberger et al.: "Recombinant antibodies possessing novel effector functions", pages 604-608, see the whole article --	1-8,14
P,X	EP, A, 0125023 (GENENTECH) 14 November 1984, see claims 1-21 --	1,11
P,X	EP, A, 0120694 (CELLTECH) 3 October 1984, see claims 1-33 --	1,11
A	WO, A, 84/00382 (NEVILLE) 2 February 1984, see claims 1-5 --	1
P,X	EP, A, 0150126 (IMMUNEX) 31 July 1985, see claims 1-19 -----	1,14

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON

INTERNATIONAL APPLICATION NO. PCT/GB 85/00392 (SA 10580)

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 17/12/85

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0068763	05/01/83	JP-A- 58059994 US-A- 4474893 CA-A- 1190873	09/04/83 02/10/84 23/07/85
EP-A- 0105521	18/04/84	JP-A- 59065099	13/04/84
WO-A- 8303971	24/11/83	AU-A- 1706283 EP-A- 0108146	02/12/83 16/05/84
EP-A- 0090898	12/10/83	JP-A- 58201723 US-A- 4464465 CA-A- 1187010	24/11/83 07/08/84 14/05/85
EP-A- 0125023	14/11/84	AU-A- 2642984 JP-A- 60155132	11/10/84 15/08/85
EP-A- 0120694	03/10/84	WO-A- 8403712 GB-A- 2137631 JP-T- 60500892	27/09/84 10/10/84 20/06/85
WO-A- 8400382	02/02/84	EP-A- 0100904 US-A- 4500637 US-A- 4520226	22/02/84 19/02/85 28/05/85
EP-A- 0150126	31/07/85	JP-A- 60222429	07/11/85

For more details about this annex :
see Official Journal of the European Patent Office, No. 12/82